EDSA - Edesa Biotech completes enrollment in mid-stage Dermatitis study cohort 1

Edesa Biotech (EDSA) announces that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the company's drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis ((ACD)), a potentially debilitating condition and occupational illness.Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa's EB01 topical treatment or a placebo cream.The company plans to initiate a blinded interim analysis, the results of which will determine the number of patients for the final part of the Phase 2b study based on probability thresholds previously approved by the FDA.Shares up nearly 3% premarket.

For further details see:

Edesa Biotech completes enrollment in mid-stage Dermatitis study cohort 1